|

KYV-101 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2/3: 1

Top Sponsors

  • Kyverna Therapeutics2

Indications

  • Refractory Lupus Nephritis1
  • Rheumatoid Arthritis (RA1
  • Dermatomyositis1
  • Systemic Sclerosis (SSc)1
  • Stiff-Person Syndrome1

Orange, California1 trial

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

University of California, Irvine

Phase 2/3

Denver, Colorado1 trial

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

University of Colorado, Denver

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.